-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Deep vein thrombosis (DVT) is part of the venous thromboembolism (VTE) spectrum, characterized by a complication of deep vein thrombosis in the cardiovascular system, and is the third most common cardiovascular disease after acute myocardial infarction and cardiovascular stroke , also a potential cause of mortality and morbidity in Africa and worldwide, with high recurrence rates
The study enrolled 200 patients diagnosed with DVT and 200 age- and sex-matched controls
Table 1 - Anticoagulants and Fibrinomodulin in Study Participants
n = 400
Among DVT patients, PC deficiency accounted for 5.
Table 2: Association of natural anticoagulants and fibrinomodulin with sex, age, family history, and acquired risk factors in deep vein thrombosis cases
n = 200
This study is the first to report evaluating the effects of natural coagulation inhibitors (PC, PS and AT-III) and fibrinolysis inhibitors (PAI-1 and TAFI) on the development of DVT in Sudan
Original source:
Abdalhabib, Ezeldine Ka; Jackson, Denise Eb; Alzahrani, Badra; Elfaki, Elyasaa; Hamza, Alneila; Alanazi, Fehaida; Ali, Elryah Ic; Algarni, Abdulrahmanc; natural anticoagulants and fibrinolytic regulatory proteins.
